Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 120 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Venlafaxine HCl Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stepped Care for Depression and Musculoskeletal Pain

NCT00118430
View directory record Official record
Conditions
Pain, Depression
Interventions
Stepped Care, Antidepressants, Usual Care
Behavioral · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 29, 2026, 11:49 PM EDT
Not yet recruiting Phase 4 Interventional

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

NCT07795593
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions
Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 4 Interventional Results available

Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)

NCT00892047
View directory record Official record
Conditions
Depression
Interventions
venlafaxine XR plus aripiprazole, venlafaxine plus placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 1 Interventional

Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels

NCT01867255
View directory record Official record
Conditions
Bariatric Surgery, Gastric Bypass, Roux-en-Y Gastric Bypass
Interventions
venlafaxine ER (extended-release) 75 mg
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 29, 2026, 11:49 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD

NCT04961190
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Prolonged Exposure Therapy, Pharmacotherapy with paroxetine or venlafaxine XR
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Menlo Park, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 3 Interventional Results available

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Not applicable Interventional Results available

Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)

NCT01609348
View directory record Official record
Conditions
Alzheimer's Disease, Depression
Interventions
Placebo, Venlafaxine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Mood and Marriage Study (TOMMS)

NCT00612807
View directory record Official record
Conditions
Major Depressive Disorder, Partner Relational Disorder (V61.10)
Interventions
Weekly marital therapy, As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Aripiprazole and Effexor XR Drug Interaction Study

NCT00362271
View directory record Official record
Conditions
Healthy
Interventions
Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Sep 29, 2026, 11:49 PM EDT
Completed No phase listed Observational

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

NCT00667121
View directory record Official record
Conditions
Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Treatment on Decision-making in Major Depression

NCT01916824
View directory record Official record
Conditions
Major Depressive Disorder, Healthy Controls
Interventions
Any FDA Approved Antidepressant
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

NCT01235338
View directory record Official record
Conditions
Healthy
Interventions
LDX + Venlafaxine XR, Venlafaxine XR + LDX
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

NCT01360866
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
93
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 29, 2026, 11:49 PM EDT
Terminated Phase 2 Interventional Results available

Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

NCT01533753
View directory record Official record
Conditions
Prostate Cancer
Interventions
Gabapentin, Venlafaxine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 29, 2026, 11:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Drugs on Cerebral Blood Flow in Patients With Mood Disorders

NCT00001478
View directory record Official record
Conditions
Healthy, Mood Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 3 Interventional

A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

NCT00122850
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Duloxetine, venlafaxine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
19
States / cities
Birmingham, Alabama • La Mesa, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 2Phase 3 Interventional

Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)

NCT00018902
View directory record Official record
Conditions
Depression
Interventions
Fluoxetine, Venlafaxine, Cognitive Behavioral Therapy (CBT), Citalopram
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 18 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Not applicable Interventional

Improving Retention of Hispanics Receiving Antidepressant Therapy

NCT00057642
View directory record Official record
Conditions
Depression, Depressive Disorder
Interventions
Sertraline, Venlafaxine Extended Release
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

NCT00177671
View directory record Official record
Conditions
Depression, Dementia
Interventions
Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 4 Interventional Results available

Project to Improve Symptoms and Mood in People With Spinal Cord Injury

NCT00592384
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Spinal Cord Injuries
Interventions
venlafaxine XR, placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 64 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2015 · Synced Sep 29, 2026, 11:49 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Obsessive Compulsive Disorder in Children

NCT00074815
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Serotonin reuptake inhibitors management, Cognitive behavioral therapy by a psychologist, Instructional cognitive behavioral therapy by a psychiatrist
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
7 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
3
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Sep 29, 2026, 11:49 PM EDT
Terminated Phase 3 Interventional Results available

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

NCT01436175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 29, 2026, 11:49 PM EDT